Metraipolis › archive › dc_1101decdc826

Long-term safety and efficacy of upadacitinib compared with adalimumab in patients with rheumatoid arthritis: 7-year data from the SELECT-COMPARE study — Europe PMC PMID:42342288

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42342288
DOI
10.1136/rmdopen-2025-006657
License (as archived)
solo-consultazione
Archived
2026-10-19T04:44:40.642Z
SHA-256 of the archived text
86d70bb832df4e53b9918181ca63eaa61ecbee076cc5d63b8318ffec6d684e33
Stable URL of this page
https://metraipolis.com/documento/dc_1101decdc826

How to cite

Long-term safety and efficacy of upadacitinib compared with adalimumab in patients with rheumatoid arthritis: 7-year data from the SELECT-COMPARE study — Europe PMC PMID:42342288 — Europe PMC (en), https://europepmc.org/article/MED/42342288 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_1101decdc826 (Metraipolis archive dc_1101decdc826, sha256 86d70bb832df4e53b9918181ca63eaa61ecbee076cc5d63b8318ffec6d684e33)
BibTeX
@misc{dc1101decdc826,
  title = {Long-term safety and efficacy of upadacitinib compared with adalimumab in patients with rheumatoid arthritis: 7-year data from the SELECT-COMPARE study — Europe PMC PMID:42342288},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42342288},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_1101decdc826; sha256 86d70bb832df4e53b9918181ca63eaa61ecbee076cc5d63b8318ffec6d684e33},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42342288. Agents can read the archived copy with the MCP tool read_document.